Literature DB >> 33671166

Effect of Unripe Banana Flour on Gut-Derived Uremic Toxins in Individuals Undergoing Peritoneal Dialysis: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.

Laila Santos de Andrade1, Fabiana Andréa Hoffmann Sardá2,3, Natalia Barros Ferreira Pereira1, Renata Rodrigues Teixeira1, Silvia Daniéle Rodrigues4, Jordana Dinorá de Lima5, Maria Aparecida Dalboni6, Danilo Takashi Aoike7, Lia Sumie Nakao4, Lilian Cuppari1,7,8.   

Abstract

In chronic kidney disease (CKD), the accumulation of gut-derived metabolites, such as indoxyl sulfate (IS), p-cresyl sulfate (pCS), and indole 3-acetic acid (IAA), has been associated with the burden of the disease. In this context, prebiotics emerge as a strategy to mitigate the accumulation of such compounds, by modulating the gut microbiota and production of their metabolites. The aim of this study was to evaluate the effect of unripe banana flour (UBF-48% resistant starch, a prebiotic) on serum concentrations of IS, pCS, and IAA in individuals undergoing peritoneal dialysis (PD). A randomized, double-blind, placebo-controlled, crossover trial was conducted. Forty-three individuals on PD were randomized to sequential treatment with UBF (21 g/day) and placebo (waxy corn starch-12 g/day) for 4 weeks, or vice versa (4-week washout). The primary outcomes were total and free serum levels of IS, pCS, and IAA. Secondary outcomes were 24 h urine excretion and dialysis removal of IS, pCS, and IAA, serum inflammatory markers [high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), interleukin-10 (IL-10), and tumor necrosis factor-α (TNF-α)], serum lipopolysaccharide LPS, and dietary intake. Of the 43 individuals randomized, 26 completed the follow-up (age = 55 ± 12 years; 53.8% men). UBF did not promote changes in serum levels of IS (p = 0.70), pCS (p = 0.70), and IAA (p = 0.74). Total serum IS reduction was observed in a subgroup of participants (n = 11; placebo: median 79.5 μmol/L (31-142) versus UBF: 62.5 μmol/L (31-133), p = 0.009) who had a daily UBF intake closer to that proposed in the study. No changes were observed in other secondary outcomes. UBF did not promote changes in serum levels of IS or pCS and IAA; a decrease in IS was only found in the subgroup of participants who were able to take 21g/day of the UBF.

Entities:  

Keywords:  chronic kidney disease; gut; prebiotic; unripe banana flour; uremic toxins

Mesh:

Substances:

Year:  2021        PMID: 33671166      PMCID: PMC7922008          DOI: 10.3390/nu13020646

Source DB:  PubMed          Journal:  Nutrients        ISSN: 2072-6643            Impact factor:   5.717


  65 in total

1.  Management of patients with chronic kidney disease.

Authors:  Francesco P Schena
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

2.  Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease.

Authors:  Christopher W McIntyre; Laura E A Harrison; M Tarek Eldehni; Helen J Jefferies; Cheuk-Chun Szeto; Stephen G John; Mhairi K Sigrist; James O Burton; Daljit Hothi; Shvan Korsheed; Paul J Owen; Ka-Bik Lai; Philip K T Li
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

3.  Protein-bound uremic toxins, inflammation and oxidative stress: a cross-sectional study in stage 3-4 chronic kidney disease.

Authors:  Megan Rossi; Katrina L Campbell; David W Johnson; Tony Stanton; David A Vesey; Jeff S Coombes; Kassia S Weston; Carmel M Hawley; Brett C McWhinney; Jacobus P J Ungerer; Nicole Isbel
Journal:  Arch Med Res       Date:  2014-04-18       Impact factor: 2.235

4.  p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease.

Authors:  Cheng-Jui Lin; Han-Hsiang Chen; Chi-Feng Pan; Chih-Kuang Chuang; Tuen-Jen Wang; Fang-Ju Sun; Chih-Jen Wu
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

5.  Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients.

Authors:  Tammy L Sirich; Natalie S Plummer; Christopher D Gardner; Thomas H Hostetter; Timothy W Meyer
Journal:  Clin J Am Soc Nephrol       Date:  2014-08-21       Impact factor: 8.237

6.  Effect of high amylose resistant starch (HAM-RS2) supplementation on biomarkers of inflammation and oxidative stress in hemodialysis patients: a randomized clinical trial.

Authors:  Hamid Tayebi Khosroshahi; Nosratola D Vaziri; Behzad Abedi; Bahlol Habibi Asl; Morteza Ghojazadeh; Wanghui Jing; Amir Mansur Vatankhah
Journal:  Hemodial Int       Date:  2018-03-13       Impact factor: 1.812

7.  Protein-Bound Uremic Toxins from Gut Microbiota and Inflammatory Markers in Chronic Kidney Disease.

Authors:  Natália A Borges; Amanda F Barros; Lia S Nakao; Carla J Dolenga; Denis Fouque; Denise Mafra
Journal:  J Ren Nutr       Date:  2016-11       Impact factor: 3.655

8.  Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis.

Authors:  R W van Olden; R T Krediet; D G Struijk; L Arisz
Journal:  J Am Soc Nephrol       Date:  1996-05       Impact factor: 10.121

9.  Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis.

Authors:  Olivier Deltombe; Wim Van Biesen; Griet Glorieux; Ziad Massy; Annemieke Dhondt; Sunny Eloot
Journal:  Toxins (Basel)       Date:  2015-09-28       Impact factor: 4.546

10.  Structural and functional differences in gut microbiome composition in patients undergoing haemodialysis or peritoneal dialysis.

Authors:  Vanessa Stadlbauer; Angela Horvath; Werner Ribitsch; Bianca Schmerböck; Gernot Schilcher; Sandra Lemesch; Philipp Stiegler; Alexander R Rosenkranz; Peter Fickert; Bettina Leber
Journal:  Sci Rep       Date:  2017-11-15       Impact factor: 4.379

View more
  7 in total

Review 1.  Nutrition, Immunology, and Kidney: Looking Beyond the Horizons.

Authors:  Baris Afsar; Rengin Elsurer Afsar; Lale A Ertuglu; Adrian Covic; Mehmet Kanbay
Journal:  Curr Nutr Rep       Date:  2022-01-26

2.  Effects of Microbiota-Driven Therapy on Circulating Indoxyl Sulfate and P-Cresyl Sulfate in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Li Chen; Junhe Shi; Xiaojuan Ma; Dazhuo Shi; Hua Qu
Journal:  Adv Nutr       Date:  2022-08-01       Impact factor: 11.567

Review 3.  The Microbiome and Uremic Solutes.

Authors:  Nadim Zaidan; Lama Nazzal
Journal:  Toxins (Basel)       Date:  2022-03-30       Impact factor: 5.075

4.  Probiotics, Prebiotics, and Synbiotics Improve Uremic, Inflammatory, and Gastrointestinal Symptoms in End-Stage Renal Disease With Dialysis: A Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Zixian Yu; Jin Zhao; Yunlong Qin; Yuwei Wang; Yumeng Zhang; Shiren Sun
Journal:  Front Nutr       Date:  2022-04-04

Review 5.  Effects of Resistant Starch on Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

Authors:  Xinyi Du; Jing Wu; Chenlin Gao; Qinqin Tan; Yong Xu
Journal:  J Diabetes Res       Date:  2022-07-18       Impact factor: 4.061

6.  Effectiveness of Microecological Preparations for Improving Renal Function and Metabolic Profiles in Patients With Chronic Kidney Disease.

Authors:  Jiaxing Tan; Huan Zhou; Jiaxin Deng; Jiantong Sun; Xiaoyuan Zhou; Yi Tang; Wei Qin
Journal:  Front Nutr       Date:  2022-09-12

Review 7.  The Human Microbiome in Chronic Kidney Disease: A Double-Edged Sword.

Authors:  Eman Wehedy; Ibrahim F Shatat; Souhaila Al Khodor
Journal:  Front Med (Lausanne)       Date:  2022-01-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.